268 related articles for article (PubMed ID: 28808734)
1. What is the true catheterization rate after intravesical onabotulinumtoxinA injection?
Patel DN; Jamnagerwalla J; Houman J; Anger JT; Eilber KS
Int Urogynecol J; 2018 Jul; 29(7):1005-1009. PubMed ID: 28808734
[TBL] [Abstract][Full Text] [Related]
2. Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
Miotla P; Cartwright R; Skorupska K; Bogusiewicz M; Markut-Miotla E; Futyma K; Rechberger T
Int Urogynecol J; 2017 Jun; 28(6):845-850. PubMed ID: 27889830
[TBL] [Abstract][Full Text] [Related]
3. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.
Osborn DJ; Kaufman MR; Mock S; Guan MJ; Dmochowski RR; Reynolds WS
Neurourol Urodyn; 2015 Sep; 34(7):675-8. PubMed ID: 24975819
[TBL] [Abstract][Full Text] [Related]
4. Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings.
Kennelly M; Green L; Alvandi N; Wehbe S; Smith JJ; MacDiarmid S; Mangel J; Schwartz M; Aboushwareb T; Murray B
Curr Med Res Opin; 2018 Oct; 34(10):1771-1776. PubMed ID: 29458265
[TBL] [Abstract][Full Text] [Related]
5. Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.
Liberman D; Milhouse O; Johnson-Mitchell M; Siegel SW
Female Pelvic Med Reconstr Surg; 2018; 24(6):404-407. PubMed ID: 28953573
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
Hsiao SM; Lin HH; Kuo HC
PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
8. Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children.
Greer T; Abbott J; Breytenbach W; McGuane D; Barker A; Khosa J; Samnakay N
J Pediatr Urol; 2016 Apr; 12(2):94.e1-6. PubMed ID: 26472538
[TBL] [Abstract][Full Text] [Related]
9. Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
Jiang YH; Kuo HC
Neurourol Urodyn; 2017 Feb; 36(2):338-343. PubMed ID: 26575613
[TBL] [Abstract][Full Text] [Related]
10. The Correlation of Diabetes Mellitus and Urinary Retention From Intravesical OnabotulinumtoxinA Injection for Overactive Bladder.
Takashima Y; Handler S; Laus K; Eckhardt S; Whitaker T; Tenggardjaja C; Yazdany T
Urogynecology (Phila); 2023 May; 29(5):511-519. PubMed ID: 36730351
[TBL] [Abstract][Full Text] [Related]
11. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study.
Liao CH; Chen SF; Kuo HC
Neurourol Urodyn; 2016 Aug; 35(6):717-23. PubMed ID: 25914349
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery.
Miotla P; Futyma K; Cartwright R; Bogusiewicz M; Skorupska K; Markut-Miotla E; Rechberger T
Int Urogynecol J; 2016 Mar; 27(3):393-8. PubMed ID: 26364180
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis.
Cui Y; Zhou X; Zong H; Yan H; Zhang Y
Neurourol Urodyn; 2015 Jun; 34(5):413-9. PubMed ID: 24676791
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.
Wang CC; Lee CL; Kuo HC
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999209
[TBL] [Abstract][Full Text] [Related]
15. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
King AB; Rapp DE
Can J Urol; 2011 Apr; 18(2):5657-9. PubMed ID: 21504656
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
Marcelissen TA; Rahnama'i MS; Snijkers A; Schurch B; De Vries P
World J Urol; 2017 Feb; 35(2):307-311. PubMed ID: 27272312
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.
Kuo HC; Liu HT; Chuang YC; Birder LA; Chancellor MB
Eur Urol; 2014 Jun; 65(6):1117-24. PubMed ID: 24555904
[TBL] [Abstract][Full Text] [Related]
18. Routine Office Assessment After OnabotulinumtoxinA Injection for Overactive Bladder Is Unnecessary to Detect Clinically Significant Voiding Dysfunction.
Aldrich ER; Pauls RN
Female Pelvic Med Reconstr Surg; 2021 Apr; 27(4):225-229. PubMed ID: 33770805
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease.
Vurture G; Peyronnet B; Feigin A; Biagioni MC; Gilbert R; Rosenblum N; Frucht S; Di Rocco A; Nitti VW; Brucker BM
Neurourol Urodyn; 2018 Nov; 37(8):2669-2677. PubMed ID: 29767449
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome.
Balzarro M; Rubilotta E; Braga A; Bassi S; Processali T; Artibani W; Serati M
Eur J Obstet Gynecol Reprod Biol; 2018 Jun; 225():228-231. PubMed ID: 29753213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
